Stock SCOL SCANDION ONCOLOGY A/S
Add to a list
To use this feature you must be a member
Log inSign up

Financials Scandion Oncology A/S

Equities

SCOL

DK0061031895

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 16:29:36 14/05/2024 BST 		5-day change 1st Jan Change
1.4 SEK +0.72% Intraday chart for Scandion Oncology A/S +5.26% -64.96%
03-21 Scandion Oncology Reports Updated Phase II Corist Data, Including Topline Overall Survival CI
03-07 Scandion Oncology Reports Second Confirms Partial Response in the Phase IIa CORIST Part 3 Trial CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 471.7 289.2 76.11 109
Enterprise Value (EV) 1 465.9 184.7 0.1001 83.03
P/E ratio -17.7 x -5.59 x -0.99 x -2.78 x
Yield - - - -
Capitalization / Revenue - - - -
EV / Revenue - - - -
EV / EBITDA -19,528,772 x -3,292,731 x -1,220 x -1,823,503 x
EV / FCF -2.87 x 1.58 x -0 x -2.07 x
FCF Yield -34.9% 63.4% -44,728% -48.3%
Price to Book 3.03 x 2.77 x 1.08 x 3.5 x
Nbr of stocks (in thousands) 32,136 32,136 40,707 40,707
Reference price 2 14.68 8.999 1.870 2.679
Announcement Date 29/04/21 24/03/22 28/03/23 15/03/24
1DKK in Million2DKK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA - -15.6 -23.86 -56.1 -82.08 -45.53
EBIT 1 -9.935 -15.6 -23.89 -56.16 -82.22 -45.8
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -9.958 -15.55 -20.65 -57.21 -82.2 -44.7
Net income 1 -8.183 -12.18 -16.27 -51.7 -76.7 -39.2
Net margin - - - - - -
EPS 2 -0.8500 -0.6395 -0.8296 -1.610 -1.884 -0.9631
Free Cash Flow 1 -11.32 -7.741 -162.4 117.1 -44.78 -40.11
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 30/04/20 30/04/20 29/04/21 24/03/22 28/03/23 15/03/24
1DKK in Million2DKK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1
Net sales -
EBITDA -
EBIT -
Operating Margin -
Earnings before Tax (EBT) -
Net income 1 -12.92
Net margin -
EPS 2 -0.5643
Dividend per Share -
Announcement Date 19/05/22
1DKK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 7.66 15.4 5.81 104 76 26
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -11.3 -7.74 -162 117 -44.8 -40.1
ROE (net income / shareholders' equity) -117% -78.8% -18.7% -39.7% -87.7% -77.3%
ROA (Net income/ Total Assets) -80% -58.3% -14.5% -23.2% -50% -46.2%
Assets 1 10.23 20.9 112.4 223.1 153.4 84.88
Book Value Per Share 2 1.060 0.9600 4.850 3.250 1.730 0.7600
Cash Flow per Share 2 0.6400 0.8100 0.1800 3.290 1.910 0.6500
Capex - - - 0.32 0.41 -
Capex / Sales - - - - - -
Announcement Date 30/04/20 30/04/20 29/04/21 24/03/22 28/03/23 15/03/24
1DKK in Million2DKK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SCANDION ONCOLOGY A/S Stock Scandion Oncology A/S
-64.96% 5.22M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+5.33% 111B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.11% 105B
BIONTECH SE Stock BioNTech SE
-12.56% 22.34B
ARGENX SE Stock argenx SE
-3.70% 21.93B
GENMAB A/S Stock Genmab A/S
-6.03% 18.59B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-35.21% 18.12B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.86% 16.96B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.10% 13.7B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.57% 12.45B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. SCOL Stock
  4. Financials Scandion Oncology A/S